Intro

This chapter discusses the findings of the IL-17 inhibitor bemikizumab presented at the ACR 2024 Convergence, with a focus on the outcomes from the B-Mobile trials. The significant increase in MRI remission rates among patients receiving the drug compared to placebo highlights its potential as an effective treatment for ankylosing spondylitis.